| Author . | Year . | Assay . | Setting . | N . | Sensitivity . | Specificity . | PFS hazard ratio . | Lead time . | Concordance rate . | Reference . |
|---|---|---|---|---|---|---|---|---|---|---|
| Kim | 2021 | Bespoke PCR | Localized RCC & mRCC | 20 | NR | NR | NR | NR | NR | Kim, 202125 |
| Chehrazi-Raffle | 2023 | Bespoke PCR (TARDIS) | mRCC | 12 | NR | NR | NR | NR | 60% | Chehrazi-Raffle26 |
| Peterson | 2022 | Bespoke PCR (Signatera, Natera Inc.) | mRCC | 21 | 81% | NR | 4.9 | NR | NR | Peterson27 |
| Basu | 2023 | Bespoke PCR (Signatera, Natera Inc.) | High risk resected or mRCC | 41 | 71% | NR | NR | 13.6 weeks | 78% | Basu28 |
| Jang | 2023 | Bespoke PCR (Signatera, Natera Inc.) | mRCC, urothelial, & prostate | 18 | 50%(for RCC) | NR | NR | 13.6 weeks | 83% | Jang, 202329 |
| Correa | 2019 | Bespoke PCR (Signatera, Natera Inc.) | Localized RCC | 42 | NR | 100% | 2.8 | NR | NR | Correa30 |
| Smigelski | 2023 | Bespoke PCR (Signatera, Natera Inc.) | Localized RCC | 82 | NR | NR | NR | NR | 65% | Smigelski31 |
| Author . | Year . | Assay . | Setting . | N . | Sensitivity . | Specificity . | PFS hazard ratio . | Lead time . | Concordance rate . | Reference . |
|---|---|---|---|---|---|---|---|---|---|---|
| Kim | 2021 | Bespoke PCR | Localized RCC & mRCC | 20 | NR | NR | NR | NR | NR | Kim, 202125 |
| Chehrazi-Raffle | 2023 | Bespoke PCR (TARDIS) | mRCC | 12 | NR | NR | NR | NR | 60% | Chehrazi-Raffle26 |
| Peterson | 2022 | Bespoke PCR (Signatera, Natera Inc.) | mRCC | 21 | 81% | NR | 4.9 | NR | NR | Peterson27 |
| Basu | 2023 | Bespoke PCR (Signatera, Natera Inc.) | High risk resected or mRCC | 41 | 71% | NR | NR | 13.6 weeks | 78% | Basu28 |
| Jang | 2023 | Bespoke PCR (Signatera, Natera Inc.) | mRCC, urothelial, & prostate | 18 | 50%(for RCC) | NR | NR | 13.6 weeks | 83% | Jang, 202329 |
| Correa | 2019 | Bespoke PCR (Signatera, Natera Inc.) | Localized RCC | 42 | NR | 100% | 2.8 | NR | NR | Correa30 |
| Smigelski | 2023 | Bespoke PCR (Signatera, Natera Inc.) | Localized RCC | 82 | NR | NR | NR | NR | 65% | Smigelski31 |
Abbreviations: RCC, renal cell carcinoma; mRCC, metastatic renal cell carcinoma; MRD, molecular residual disease; NR, not reported; TARDIS, targeted digital sequencing.
| Author . | Year . | Assay . | Setting . | N . | Sensitivity . | Specificity . | PFS hazard ratio . | Lead time . | Concordance rate . | Reference . |
|---|---|---|---|---|---|---|---|---|---|---|
| Kim | 2021 | Bespoke PCR | Localized RCC & mRCC | 20 | NR | NR | NR | NR | NR | Kim, 202125 |
| Chehrazi-Raffle | 2023 | Bespoke PCR (TARDIS) | mRCC | 12 | NR | NR | NR | NR | 60% | Chehrazi-Raffle26 |
| Peterson | 2022 | Bespoke PCR (Signatera, Natera Inc.) | mRCC | 21 | 81% | NR | 4.9 | NR | NR | Peterson27 |
| Basu | 2023 | Bespoke PCR (Signatera, Natera Inc.) | High risk resected or mRCC | 41 | 71% | NR | NR | 13.6 weeks | 78% | Basu28 |
| Jang | 2023 | Bespoke PCR (Signatera, Natera Inc.) | mRCC, urothelial, & prostate | 18 | 50%(for RCC) | NR | NR | 13.6 weeks | 83% | Jang, 202329 |
| Correa | 2019 | Bespoke PCR (Signatera, Natera Inc.) | Localized RCC | 42 | NR | 100% | 2.8 | NR | NR | Correa30 |
| Smigelski | 2023 | Bespoke PCR (Signatera, Natera Inc.) | Localized RCC | 82 | NR | NR | NR | NR | 65% | Smigelski31 |
| Author . | Year . | Assay . | Setting . | N . | Sensitivity . | Specificity . | PFS hazard ratio . | Lead time . | Concordance rate . | Reference . |
|---|---|---|---|---|---|---|---|---|---|---|
| Kim | 2021 | Bespoke PCR | Localized RCC & mRCC | 20 | NR | NR | NR | NR | NR | Kim, 202125 |
| Chehrazi-Raffle | 2023 | Bespoke PCR (TARDIS) | mRCC | 12 | NR | NR | NR | NR | 60% | Chehrazi-Raffle26 |
| Peterson | 2022 | Bespoke PCR (Signatera, Natera Inc.) | mRCC | 21 | 81% | NR | 4.9 | NR | NR | Peterson27 |
| Basu | 2023 | Bespoke PCR (Signatera, Natera Inc.) | High risk resected or mRCC | 41 | 71% | NR | NR | 13.6 weeks | 78% | Basu28 |
| Jang | 2023 | Bespoke PCR (Signatera, Natera Inc.) | mRCC, urothelial, & prostate | 18 | 50%(for RCC) | NR | NR | 13.6 weeks | 83% | Jang, 202329 |
| Correa | 2019 | Bespoke PCR (Signatera, Natera Inc.) | Localized RCC | 42 | NR | 100% | 2.8 | NR | NR | Correa30 |
| Smigelski | 2023 | Bespoke PCR (Signatera, Natera Inc.) | Localized RCC | 82 | NR | NR | NR | NR | 65% | Smigelski31 |
Abbreviations: RCC, renal cell carcinoma; mRCC, metastatic renal cell carcinoma; MRD, molecular residual disease; NR, not reported; TARDIS, targeted digital sequencing.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
